Philipp Knigshofer

List of Publications by Year in Descending Order

10 papers	429 citations	6 h-index	10 g-index
10 ext. papers	739 ext. citations	5.7 avg, IF	3.93 L-index

#	Paper	IF	Citations
10	Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension.. *Advances in Medical Sciences*, **2022**, 67, 154-162	2.8	0
9	Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies. *Hepatology*, **2021**,	11.2	1
8	The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. *Biomedicines*, **2021**, 9,	4.8	15
7	Nuclear receptors in liver fibrosis. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2021**, 1867, 166235	6.9	4
6	Recent Advances in Practical Methods for Liver Cell Biology: A Short Overview. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	7
5	Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats. *United European Gastroenterology Journal*, **2020**, 8, 1174-1185	5.3	6
4	Vascular Targets for the Treatment of Portal Hypertension. *Seminars in Liver Disease*, **2019**, 39, 483-501	7.3	12
3	Detection of Various Microplastics in Human Stool: A Prospective Case Series. *Annals of Internal Medicine*, **2019**, 171, 453-457	8	357
2	The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. *Scientific Reports*, **2018**, 8, 9372	4.9	24
1	Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats. *Journal of Visualized Experiments*, **2018**,	1.6	3